These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15830727)

  • 21. In vitro and in vivo availability of spironolactone from oral dosage forms.
    Chao AY; Sanvordeker DR; Zagarella J; Mattes K; Nicholova B; Karim A
    J Pharm Sci; 1976 Nov; 65(11):1630-4. PubMed ID: 993995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-performance liquid chromatography methods for the separation and quantitation of spironolactone and its degradation products in aqueous formulations and of its metabolites in rat serum.
    Kaukonen AM; Vuorela P; Vuorela H; Mannermaa JP
    J Chromatogr A; 1998 Feb; 797(1-2):271-81. PubMed ID: 9542120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-nanoemulsifying drug delivery system (SNEDDS) of the poorly water-soluble grapefruit flavonoid Naringenin: design, characterization, in vitro and in vivo evaluation.
    Khan AW; Kotta S; Ansari SH; Sharma RK; Ali J
    Drug Deliv; 2015; 22(4):552-61. PubMed ID: 24512268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability.
    Shen G; Cheng L; Wang LQ; Zhang LH; Shen BD; Liao WB; Li JJ; Zheng J; Xu R; Yuan HL
    Chin J Nat Med; 2016 Oct; 14(10):757-768. PubMed ID: 28236405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of Pharmacokinetic Parameters of Daidzein-Containing Nanosuspension and Nanoemulsion Formulations After Oral Administration to Rats.
    Demirtürk E; Ugur Kaplan AB; Cetin M; Akıllıoğlu K; Dönmez Kutlu M; Köse S; Aksu F
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):247-257. PubMed ID: 35018554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
    Dudhipala N; Janga KY
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone.
    McInnes GT; Asbury MJ; Ramsay LE; Shelton JR; Harrison IR
    J Clin Pharmacol; 1982; 22(8-9):410-7. PubMed ID: 7130430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solid self-microemulsifying drug delivery system of ritonavir.
    Deshmukh A; Kulkarni S
    Drug Dev Ind Pharm; 2014 Apr; 40(4):477-87. PubMed ID: 23465049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.
    Mohsin K; Alamri R; Ahmad A; Raish M; Alanazi FK; Hussain MD
    Int J Nanomedicine; 2016; 11():2829-38. PubMed ID: 27366063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Studies of biological availability. A critical assessment based on a study of spironolactone preparations].
    Rameis H; Bacher S
    Wien Med Wochenschr; 1988 Apr; 138(6-7):156-60. PubMed ID: 3394332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The metabolism and biopharmaceutics of spironolactone in man.
    Overdiek HW; Merkus FW
    Rev Drug Metab Drug Interact; 1987; 5(4):273-302. PubMed ID: 3333882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physicochemical, Pharmacodynamic and Pharmacokinetic Characterization of Soluplus Stabilized Nanosuspension of Tacrolimus.
    Varshosaz J; Minayian M; Yazdekhasti S
    Curr Drug Deliv; 2017; 14(4):521-535. PubMed ID: 27697037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of oral bioavailability enhancing formulations during drug discovery.
    Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
    Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel bicephalous heterolipid based self-microemulsifying drug delivery system for solubility and bioavailability enhancement of efavirenz.
    Chaudhari KS; Akamanchi KG
    Int J Pharm; 2019 Apr; 560():205-218. PubMed ID: 30742985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spironolactone. II. Bioavailability.
    Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
    Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of lipid-based excipients and their composition on the bioavailability of antiretroviral self-emulsifying formulations.
    Chudasama A; Patel V; Nivsarkar M; Vasu K; Shishoo C
    Drug Deliv; 2015; 22(4):531-40. PubMed ID: 24601856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profiling gene expression dynamics underpinning conventional testing approaches to better inform pre-clinical evaluation of an age appropriate spironolactone formulation.
    Russell C; Hussain M; Huen D; Rahman AS; Mohammed AR
    Pharm Dev Technol; 2021 Jan; 26(1):101-109. PubMed ID: 33078682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability.
    Hashem FM; Al-Sawahli MM; Nasr M; Ahmed OA
    Drug Des Devel Ther; 2015; 9():3141-52. PubMed ID: 26150693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
    Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
    Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study on solid self-nanoemulsifying drug delivery and solid dispersion system for enhanced solubility and bioavailability of ezetimibe.
    Rashid R; Kim DW; Yousaf AM; Mustapha O; Fakhar Ud Din ; Park JH; Yong CS; Oh YK; Youn YS; Kim JO; Choi HG
    Int J Nanomedicine; 2015; 10():6147-59. PubMed ID: 26491288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.